SAB Biotherapeutics UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good morning, everyone. Thank you for joining us on our next fireside session here at the UBS Global Biopharma Conference. I'm Michael Yee, a managing director and senior biotechnology analyst at UBS. I'm very pleased to have SAB Biotherapeutics with us, and joining us up on stage is the Chief Executive Officer, Sam Reich. It's great to see you, Sam.
Thank you for having me. It's a pleasure to be here.
Thank you. Well, maybe I think first and most important is, as people continue to learn more about SAB, that we understand your technology, we understand what makes your product unique. If you could just give us a brief introduction to SAB and specifically your product and what makes it unique, that'd be a great introduction, and we can go into some of the details.
Of course. SAB BIO is a late-stage clinical biopharmaceutical company. Our mission is to transform what it means to get a T1D diagnosis by preserving the patient's ability to make their own insulin. Our drug is in a pivotal phase IIb trial. It is a human anti-thymocyte immunoglobulin, and for treating newly diagnosed type 1 diabetes, again, to preserve the patient's ability to make their own insulin. The mechanism of action is validated by a rabbit anti-thymocyte globulin, which has been tested in multiple clinical trials and proven to preserve C-peptide, which is the marker of the patient's endogenous insulin, and reduce HbA1c, showing improved glycemic control. That rabbit protein leads to an adverse event called serum sickness, which is not well accepted by the clinical community, and the patients certainly don't like it. It also can't be redosed.
It's a one and done, and this is a chronic disease that needs to be redosed. We have solved that problem. Our platform allows us to make a human version of that, and SAB-142 is a human version of anti-thymocyte globulin. We can rely on the efficacy because it's that same clinically validated mechanism of action, and we've solved the safety problem. We've shown in a phase I, we can give the drug safely without causing serum sickness, and we can reliably redose for this chronic condition that needs lifetime dosing.
For those that have been doing work or can be doing work in type 1 diabetes, if you read the data for thymoglobulin, an antibody that's generated through rabbits, it does work. It is proven efficacious, but there's side effects, and it cannot be redosed.
Correct. That is a problem.
However, it does have statistically significant improvements in C-peptide and A1c.
Yes. Impressive. But has issues.
Can you describe how your product is manufactured? Because I think that's particularly unique, and I'd love to go take a tour.
Yeah, we'd love to have you.
Okay. Tell us about that.
Thymoglobulin, the rabbit version, and SAB-142, the human version, are plasma-derived IgG, and you need a source of the plasma. Thymoglobulin is made by vaccinating rabbits, regular wild-type rabbits, with human thymus, and then that rabbit has an immune response and makes a population of IgG or antibodies that are enriched for targeting thymocytes or T-cells. The plasma's collected from those rabbits, and the IgG is purified from that plasma, and the drug product is purified IgG that's enriched for antibodies that target human thymocytes. But it's rabbit, it's rabbit protein. SAB's proprietary technology is a transchromosomic cow, and that cow makes human antibodies and not bovine antibodies. We vaccinate the cow with human thymus tissue, just like thymoglobulin.
The cow then becomes a plasma donor, and just so you know, humans donate their plasma on a regular basis, so the cows aren't doing anything humans don't volunteer for. The plasma is then, just like the thymoglobulin, enriched for antibodies that target T-cells. That becomes the source for manufacturing. We purify the IgG from that plasma, and the drug product, SAB-142, is purified human IgG targeting T-cells.
Fantastic. You have a high throughput site, call it a farm, but it's a site where all of these cows are Yeah that you're able to make this in a high throughput production that would be supporting commercial production of this product.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
